330.05 -0.55 (-0.17%)

1.3M NSE+BSE Volume

NSE 06 Jun, 2025 3:31 PM (IST)

Regulatory Approval
Biocon receives CDSCO nod for Liraglutide, used to treat Type 2 diabetes in adults and children See details

Biocon Ltd. Investor Presentations